ClinicalTrials.gg
CompletedNCT05184088CArdiagUpdated Oct 26, 2026

Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis

A Phase 3 interventional study of [18F]florbetaben in Cardiac Amyloidosis, AL Amyloidosis and ATTR Amyloidosis, sponsored by Lantheus Germany GmbH. Completed at 14 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Lantheus Germany GmbH (part of Lantheus Holdings, Inc.) · Phase 3, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
244
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies in Amyloid Neuropathies, Familial with a site in Germany — 12 open to participants now, 13 under way, 1 of them phase 3. Amyloid Neuropathies, Familial · Germany.

Enrollment
4th of 13
244 · median 206
Started
2023
with 2 others
Phase 3
8 of 28
1 open now
Registered
17th of 28
by date

Among the 28 studies in Amyloid Neuropathies, Familial with a site in Germany, this one is the 4th largest by enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2023, is one of 8 in phase 3, and was the 17th registered.

Amyloid Neuropathies, Familial

188 studies on the registry are indexed under Amyloid Neuropathies, Familial; 94 are open to participants now.

Browse Amyloid Neuropathies, Familial studies →

Open to participants now

12 of the 28 studies in Amyloid Neuropathies, Familial with a site in Germany are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 69 Amyloid Neuropathies, Familial studies recruiting now, 53 (77%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Amyloid Neuropathies, Familial with a site in Germany, or all of them as a file.
02

Study summary

This is an open-label, multi-center pivotal Phase 3 study to visually and quantitatively assess PET images obtained after single application of 300 MBq [18F]florbetaben and PET scanning of patients with suspected cardiac amyloidosis.

Read the detailed description

This is an open-label, multi-center pivotal Phase 3 study to visually and quantitatively assess PET images obtained after single application of 300 MBq [18F]florbetaben and PET scanning of patients with suspected cardiac amyloidosis or with a putative diagnosis of cardiac amyloidosis but with remaining diagnostic uncertainty (e.g., unclear etiology or cardiac manifestation) or patients with diagnosis of amyloidosis but unclear cardiac involvement.

The diagnostic efficacy of the visual and quantitative assessments of [18F]florbetaben PET images for diagnosis of cardiac AL Amyloidosis will be determined by comparison to the standard of truth (SoT) obtained through standard of care clinical diagnosis.

03

Conditions studied

  • Cardiac Amyloidosis
  • AL Amyloidosis
  • ATTR Amyloidosis

Keywords

  • AL Amyloidosis
  • ATTR Amyloidosis
  • Cardiac Amyloidosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females age ≥18 years
  • Able to understand, sign and date written
  • Written informed consent must be obtained before any study procedures are performed
  • Subjects being considered for a possible diagnosis of cardiac amyloidosis by
  • 1. One of the following conditions:

    • Established systemic amyloidosis without proven cardiac involvement,
    • Known plasma cell dyscrasia (MGUS, multiple myeloma),
    • Pathological free light chain levels in urine or serum,
    • Presence of heart failure with preserved
  • 2. AND one of the following parameters, indicative of cardiac manifestation:

    • Mean (left ventricular (LV) wall + septum) thickness >12mm as measured by echocardiography or CMR in absence of other known cause of left ventricular hypertrophy (LVH),
    • NT-proBNP >335 ng/L (in case a value for NT-proBNP is not available, BNP > 81ng/L may be used instead)
  • Planned diagnostic procedure to establish diagnosis and cardiac involvement (e.g., endomyocardial or extracardiac biopsy in conjunction with cardiac magnetic resonance imaging/echocardiography or bone scintigraphy)
  • Female subjects must be documented by medical records or physician's note to be either surgically sterile (by means of hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or for at least 1 year (no menses for 12 months without an alternative medical cause). If they are of , they must commit to use of a highly effective measure for at least one week following the PET scan (including combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal or transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable or implantable), intrauterine device, intrauterine hormone-releasing system, bilaterial tubal occlusion, vasectomised parner or secual abstinence).
  • Male subjects and their partners of childbearing potential must commit to the use of a highly effective method of contraception for a minimum of 90 days following the PET scan (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal or transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable or implantable), intrauterine device, intrauterine hormone-releasing system, bilaterial tubal occlusion, male subjects with vasectomy or sexual abstinence)
  • Male subjects must commit to not donate sperm for a minimum of 90 days after the PET scan

Exclusion criteria

Exclusion Criteria:

  • Any known allergic reactions or towards any compound of the study drug
  • Severe hepatic impairment (/ALT >5 x ; >3 x ULN)
  • Inability to lay flat for up to 60 min
  • Pregnant, lactating or breastfeeding
  • Unwilling and/or unable to cooperate with study procedures
  • Having been administered a radiopharmaceutical within 10 radioactive half-lives prior to study drug administration in this study
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
244 participants (actual)

Study arms

  • Experimental
    Patients with suspected cardiac amyloidosis

    After enrolment, patients will be subjected to diagnostic procedures according to standard of care to resolve diagnostic uncertainties and to clarify possible cardiac involvement. The results of the clinical work-up will be used a standard of truth, i.e. patients with initially suspected cardiac amyloidosis that where subsequently clinically diagnosed with cardiac AL Amyloidosis, cardiac ATTR Amyloidosis, other cardiac Amyloidosis or non cardiac amyloidosis.

    Drug: [18F]florbetaben

Interventions

  • All enrolled patients will undergo \[18F\]florbetaben PET imaging.

    Also known as: Neuraceq

06

What researchers measure

Primary outcomes

  1. Sensitivity and specificity of the visual assessment of [18F]florbetaben PET images for the diagnosis of cardiac AL amyloidosis.

    The results from the visual assessment of \[18F\]florbetaben PET images are compared to the clinical diagnosis established through histological verification of the presence or absence of AL amyloidosis with cardiac involvement determined either through endomyocardial biopsy or through extracardiac biopsy in conjunction with typical CMR or echocardiography imaging features as the standard of truth.

    Time frame: Up to 12 weeks

Secondary outcomes

  1. Sensitivity and specificity of [18F]florbetaben PET for the diagnosis of cardiac AL amyloidosis using quantification.

    The sensitivity and specificity of \[18F\]florbetaben PET for the diagnosis of cardiac AL amyloidosis will be determined by using quantitative image analysis.

    Time frame: Up to 12 weeks

  2. Correlation of quantitative [18F]florbetaben PET results with left ventricular ejection fraction (LV EF) and left ventricular mass (LV mass).

    Correlation of quantitative \[18F\]florbetaben PET results with left ventricular ejection fraction (LV EF) and left ventricular mass (LV mass).

    Time frame: Up to 12 weeks

  3. Correlation of quantitative [18F]florbetaben PET results with AL CA stage I - IV based on FLC-diff, cTnT and NT-proBNP levels.

    Correlation of quantitative \[18F\]florbetaben PET results with AL CA stage I - IV based on FLC-diff, cTnT and NT-proBNP levels.

    Time frame: Up to 12 weeks

  4. Impact of PET imaging (AL-CA/non AL-CA) on diagnostic thinking and patient management will be assessed with physician's questionnaires before and after the diagnostic work-up, and after receipt of the PET results.

    The impact of PET imaging (AL-CA/non AL-CA) on diagnostic thinking and patient management will be assessed with physician's questionnaires before and after the diagnostic work-up, and after receipt of the PET results.

    Time frame: Up to 14 weeks

  5. Number of adverse events

    Safety will be evaluated by collection of Adverse Events.

    Time frame: Up to 17 days after imaging visit

Other outcomes

  1. Sensitivity and specificity of [18F]florbetaben PET images for a differential diagnosis between AL CA, ATTR CA and non CA will be assessed.

    In this exploratory endpoint the sensitivity and specificity of \[18F\]florbetaben PET images for a differential diagnosis between AL CA, ATTR CA and non CA will be assessed.

    Time frame: Up to 12 weeks

07

Study locations

14 sites
  • St Luke's Hospital
    Kansas City, Kansas 64111, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • University of Pittsburgh
    Pittsburgh, Pennsylvania 15213, United States
  • University of Augsburg
    Augsburg, 86156, Germany
  • Charite Berlin
    Berlin, 13353, Germany
  • University of Essen
    Essen, 45147, Germany
  • HOPA Hamburg
    Hamburg, 22767, Germany
  • University of Heidelberg
    Heidelberg, 69120, Germany
  • University of Würzburg
    Würzburg, 97080, Germany
  • Hospital University Bellvitge
    Barcelona, 08907, Spain
  • Hospital University Puerta de Hierro
    Madrid, 28222, Spain
  • Clínica Universidad de Navarra
    Pamplona, 31008, Spain
  • University of Salamanca
    Salamanca, 37007, Spain
  • Royal Free Hospital
    London, NW3 2PF, United Kingdom
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2023 to primary completion in Apr 2026, 39 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2022
First posted
Jan 11, 2022
StartActual
Jan 13, 2023
Primary completionActual
Apr 21, 2026
CompletionActual
May 5, 2026
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers and verification date
1 update, last Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Minor edits only
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05184088
Collaborators
pharmtrace klinische Entwicklung GmbH
Responsible party
Sponsor
First posted
Jan 11, 2022
Start date
Jan 13, 2023
Primary completion
Apr 21, 2026
Completion
May 5, 2026
Last update
Oct 26, 2026

Study contacts

Andrew Stephens, MD, PhD
study director · Lantheus Germany GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Florbetaben f-18

Start the discussion